Considering that PD-L1 glycosylation is strongly influenced by EGFR signalling and other tyrosine kinases (TKs), TK inhibitors can synergize with PD-1 blockade to restore anti-tumor immunity. The gene discussed is EGFR; the disease is neoplasm.